Clinical factor | Entire cohort [cases (%)] | CNS relapse cohort [cases (%)] | ||||
---|---|---|---|---|---|---|
CHOP | R-CHOP | P | CHOP | R-CHOP | P | |
Total | 135 | 376 | Â | 11 | 14 | Â |
Age | Â | Â | 0.563 | Â | Â | 1.000 |
 ≤60 years | 98 (72.6) | 263 (69.9) |  | 8 (72.7) | 10 (71.4) |  |
 >60 years | 37 (27.4) | 113 (30.1) |  | 3 (27.3) | 4 (28.6) |  |
Gender | Â | Â | 0.694 | Â | Â | 0.115 |
 Male | 76 (56.3) | 219 (58.2) |  | 5 (45.5) | 11 (78.6) |  |
 Female | 59 (43.7) | 157 (41.8) |  | 6 (54.5) | 3 (21.4) |  |
Stage | Â | Â | 0.892 | Â | Â | 0.434 |
 I or II | 77 (57.0) | 217 (57.7) |  | 5 (45.5) | 4 (28.6) |  |
 III or IV | 58 (43.0) | 159 (42.3) |  | 6 (54.5) | 10 (71.4) |  |
B symptoms | Â | Â | 0.663 | Â | Â | 1.000 |
 No | 95 (70.4) | 272 (72.3) |  | 7 (63.6) | 8 (57.1) |  |
 Yes | 40 (29.6) | 104 (27.7) |  | 4 (36.4) | 6 (42.9) |  |
Bulky diseasea,b | Â | Â | 0.238 | Â | Â | 0.500 |
 No | 91 (67.4) | 252 (67.0) |  | 6 (54.5) | 8 (57.1) |  |
 Yes | 10 (7.4) | 17 (4.5) |  | 0 (0) | 2 (14.3) |  |
Involved extranodal sitesc | Â | Â | 0.617 | Â | Â | 0.414 |
 ≤1 | 112 (83.0) | 303 (80.6) |  | 8 (72.7) | 7 (50) |  |
 >1 | 23 (17.0) | 71 (18.9) |  | 3 (27.3) | 7 (50) |  |
Sinus involvement | Â | Â | 0.971 | Â | Â | 0.604 |
 No | 119 (88.1) | 331 (88.0) |  | 10 (90.9) | 11 (78.6) |  |
 Yes | 16 (11.9) | 45 (12.0) |  | 1 (9.1) | 3 (21.4) |  |
Bone involvement | Â | Â | 0.947 | Â | Â | 0.407 |
 No | 120 (88.9) | 335 (89.1) |  | 9 (81.8) | 9 (64.3) |  |
 Yes | 15 (11.1) | 41 (10.9) |  | 2 (18.2) | 5 (35.7) |  |
Bone marrow involvement | Â | Â | 0.177 | Â | Â | 0.230 |
 No | 133 (98.5) | 360 (95.7) |  | 11 (100) | 11 (78.6) |  |
 Yes | 2 (1.5) | 16 (4.3) |  | 0 (0) | 3 (21.4) |  |
Liver involvement | Â | Â | 0.792 | Â | Â | 0.487 |
 No | 131 (97.0) | 361 (96.0) |  | 11 (100) | 12 (85.7) |  |
 Yes | 4 (3.0) | 15 (4.0) |  | 0 (0) | 2 (14.3) |  |
Testicular involvement | Â | Â | 0.526 | Â | Â | 1.000 |
 No | 131 (97.0) | 368 (97.9) |  | 11 (100) | 13 (92.9) |  |
 Yes | 4 (3.0) | 8 (2.1) |  | 0 (0) | 1 (7.1) |  |
Renal involvement | Â | Â | 0.782 | Â | Â | 0.661 |
 No | 130 (96.3) | 360 (95.7) |  | 9 (81.8) | 10 (71.4) |  |
 Yes | 5 (3.7) | 16 (4.3) |  | 2 (18.2) | 4 (28.6) |  |
Breast involvement |  |  | 0.318 |  |  | – |
 No | 130 (96.3) | 368 (97.9) |  | 11 (100) | 14 (100) |  |
 Yes | 5 (3.7) | 8 (2.1) |  | 0 (0) | 0 (0) |  |
Female genital tract involvement |  |  | 0.063 |  |  | – |
 No | 131 (97.0) | 373 (99.2) |  | 11 (100) | 14 (100) |  |
 Yes | 4 (3.0) | 3 (0.8) |  | 0 (0) | 0 (0) |  |
IPI | Â | Â | 0.096 | Â | Â | 0.208 |
 0–2 | 113 (83.7) | 289 (76.9) |  | 9 (81.8) | 7 (50.0) |  |
 3–5 | 22 (16.3) | 87 (23.1) |  | 2 (18.2) | 7 (50.0) |  |
LDHd | Â | Â | 0.768 | Â | Â | 0.677 |
 ≤1 ULNe | 79 (58.5) | 215 (57.2) |  | 3 (27.3) | 6 (42.9) |  |
 >1 ULN | 55 (40.7) | 159 (42.3) |  | 8 (72.7) | 8 (57.1) |  |
ALB | Â | Â | 0.464 | Â | Â | 0.656 |
 <35 g/L | 114 (84.4) | 327 (87.0) |  | 4 (36.4) | 3 (21.4) |  |
 ≥35 g/L | 21 (15.6) | 49 (13.0) |  | 7 (63.6) | 11 (78.6) |  |
ALPf | Â | Â | 0.529 | Â | Â | 1.000 |
 ≤110 U/L | 119 (88.1) | 341 (90.7) |  | 8 (72.7) | 10 (71.4) |  |
 >110 U/L | 15 (11.1) | 35 (9.3) |  | 3 (27.3) | 4 (28.6) |  |
IT chemotherapy prophylaxisg | Â | Â | 0.640 | Â | Â | 0.661 |
 No | 117 (86.7) | 329 (87.5) |  | 9 (81.8) | 10 (71.4) |  |
 Yes | 18 (13.3) | 44 (11.7) |  | 2 (18.2) | 4 (28.6) |  |
TTCh | Â | Â | 0.016 | Â | Â | 0.003 |
 ≤108 days | 54 (40.0) | 207 (55.1) |  | 0 (0) | 7 (50.0) |  |
 >108 days | 67 (49.6) | 155 (41.2) |  | 10 (90.9) | 3 (21.4) |  |